Abstract: ObjectiveTo study recent clinical efficacy and adverse reactions of pemetrexed in combination with cisplatin in the treatment of advanced breast cancer . MethodsUsing envelopes andrandomly the patients were dividing into treatment group and control group. The treatment group with 18 cases of advanced breast cancer were treated with pemetrexed and cisplatin while in the control group , 23 cases advanced breast cancer patients were treated with gemcitabine and cisplatin with 21 days as a cycle. The efficacy and adverse reactions were determined according to the WHO on Response Evaluation Criteria in Solid Tumors therapy and chemotherapy toxicity evaluation criteria. ResultsTumor control rate in the treatment group was 83.3%（15/18）,while  in the control group was 78.3%（18/23）, and the difference was not statistically significant (χ2=0.000 94，P> 0.05); while the adverse reactions differenced between the treatment group and the control group were statistically significant（bone marrow suppression χ2=9.23；fatigue χ2=4.96；nausea and vomiting χ2=4.98；diarrhea χ2=4.45；skin rash χ2=5.03，P<0.05）. ConclusionPemetrexed combined with cisplatin in patients with advanced breast cancer has a good effect, and the adverse reaction is low.

Key words: Cisplatin, Breast neoplasms, Therapeutic uses